Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: -others

Oncolytic virus TG6002 safety and activity after intrahepatic artery administration in patients with liver-dominant metastatic colorectal cancer

A. Samson, et al. AACR 2023 – Download the Poster

Published 17 April 2023
Categorized as -others, 2023, 2025, Publication

Selection of an optimal anti-PD-L1 single domain antibody format for the vectorization into oncolytic vaccinia virus and the generation of bispecific immunomodulators

JB. Marchand et al.AACR 2023Download the poster herePoster Presentation

Published 17 April 2023
Categorized as -others, 2023, Invir.IO, Publication

Extracellular vesicles (EV): mediators of therapeutic vaccination? In vivo and in vitro characterization of EVs generated after infection of human and murine cells with therapeutic poxviruses

L. Walther et al.AACR 2023Download the poster herePoster Presentation

Published 16 April 2023
Categorized as -others, 2023, Publication

Pseudocowpox virus, a novel vector to enhance the therapeutic efficacy of antitumor vaccination

Rodrigo Nalio Ramos, et al. Clinical and Translational Immunology, May 8 2022 – Read the article Publication

Published 8 May 2022
Categorized as -others, 2022, Publication

Bioavailability and activity of oncolytic virus TG6002 after intravenous administration in patients with advanced gastrointestinal carcinomas

P. Cassier et al. ESMO 2021 Download the poster here Poster Presentation

Published 16 September 2021
Categorized as -others, 2021, Publication, TG6002

3D organoids derived from patients’ lung tumors: a tool for investigating the potential of oncolytic viruses

Poster BT-001 Hélène Lê et al. EUROoCS 2021 Download the Poster here Poster Presentation

Published 1 July 2021
Categorized as -others, -others, 2021, BT-001, Publication, TG6002

Oncolytic virus TG6002 locates to tumors after intravenous infusion and induces tumor-specific expression of a functional pro-drug activating enzyme in patients with advanced gastrointestinal carcinomas

K. Bendjama et al. AACR 2021 Read the abstract here – Download the poster here Poster Presentation

Published 9 April 2021
Categorized as -others, 2021, Invir.IO, Publication, TG6002

Transgene presents initial Phase I data of TG6002, highlighting the potential of the intravenous administration of its oncolytic viruses

20210409 – TG6002 AACR EN

Published 9 April 2021
Categorized as -others, 2021, Press release, TG6002

Immunocompetent cancer-on-chip models to assess immuno-oncology therapy

Tengku Ibrahim Maulana, et al. Adv Drug Deliv Rev., March 30 2021 – Read the article Publication

Published 30 March 2021
Categorized as -others, 2021, Publication

Safety, biodistribution and viral shedding of oncolytic vaccinia virus TG6002 administered intravenously in healthy beagle dogs

Jérémy Béguin, et al. Sci Rep., January 26 2021 – Read the article Publication

Published 26 January 2021
Categorized as -others, 2021, Publication, TG6002

Posts pagination

Newer posts Page 1 … Page 3 … Page 10 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu